Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Fimepinostat · CUDC-907

Small molecule · Inhibitor of PI3K class I and histone deacetylase · developed by Curis

Phase 2 Most advanced trial (none active)
CRIS Developer
2 Registered trials

What is Fimepinostat?

Fimepinostat is an orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes. It prevents activation of the PI3K-AKT-mTOR pathway and induces apoptosis in tumor cells. It is studied in relapsed and/or refractory lymphomas including diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CUDC-907
Drug type
Small molecule
Targets
PI3K class I, histone deacetylase
Mechanism
Inhibitor of PI3K class I and histone deacetylase
Pathways
PI3K/AKT/mTOR, apoptosis
Therapy area
Oncology
Developer
Curis, Inc. (CRIS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
3S9RX35S5X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02674750 Phase 2 Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc… Completed CRIS
NCT01742988 Phase 1 Lymphoma Completed CRIS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Double-expressor Lymphoma (DEL)Double-hit Lymphoma (DHL)High-grade B-cell Lymphoma (HGBL)LymphomaRefractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory LymphomaRelapsed and/or Refractory LymphomaRelapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)Relapsed LymphomaTriple-hit Lymphoma (THL)

More from Curis

Cenopodlin Phase 1 CUDC-101 Phase 1 Emavusertib Phase 1/2 GDC-0917 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CRIS page.

Follow CRIS, the company behind Fimepinostat

See CRIS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRIS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.